-
2
-
-
34247220899
-
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier
-
Ambati BK, Patterson E, Jani P, et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol. 2007;91:505-508.
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 505-508
-
-
Ambati, B.K.1
Patterson, E.2
Jani, P.3
-
3
-
-
33746621996
-
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision
-
Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103:11405-11410.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 11405-11410
-
-
Cursiefen, C.1
Chen, L.2
Saint-Geniez, M.3
-
4
-
-
0031965601
-
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization
-
Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39: 18-22.
-
(1998)
Invest Ophthalmol Vis Sci
, vol.39
, pp. 18-22
-
-
Amano, S.1
Rohan, R.2
Kuroki, M.3
-
5
-
-
20444482034
-
Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo
-
Singh N, Amin S, Richter E, et al. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci. 2005;46:1647-1652.
-
(2005)
Invest Ophthalmol Vis Sci
, vol.46
, pp. 1647-1652
-
-
Singh, N.1
Amin, S.2
Richter, E.3
-
6
-
-
0033856243
-
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
-
Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
-
(2000)
Invest Ophthalmol Vis Sci
, vol.41
, pp. 2514-2522
-
-
Philipp, W.1
Speicher, L.2
Humpel, C.3
-
7
-
-
0033941677
-
Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization
-
Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19:526-533.
-
(2000)
Cornea
, vol.19
, pp. 526-533
-
-
Cursiefen, C.1
Rummelt, C.2
Kuchle, M.3
-
8
-
-
33845968846
-
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization
-
Singh N, Higgins E, Amin S, et al. Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea. 2007;26: 65-72.
-
(2007)
Cornea
, vol.26
, pp. 65-72
-
-
Singh, N.1
Higgins, E.2
Amin, S.3
-
9
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
10
-
-
23044505200
-
Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration
-
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
-
(2005)
Ophthalmic Surg Lasers Imaging
, vol.36
, pp. 331-335
-
-
Rosenfeld, P.J.1
Moshfeghi, A.A.2
Puliafito, C.A.3
-
11
-
-
33646455655
-
Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection
-
Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26: 354-356.
-
(2006)
Retina
, vol.26
, pp. 354-356
-
-
Davidorf, F.H.1
Mouser, J.G.2
Derick, R.J.3
-
12
-
-
34247519047
-
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
-
Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
-
(2007)
Br J Ophthalmol
, vol.91
, pp. 804-807
-
-
Manzano, R.P.1
Peyman, G.A.2
Khan, P.3
-
13
-
-
34247494559
-
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
-
Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
-
(2007)
Invest Ophthalmol Vis Sci
, vol.48
, pp. 2545-2552
-
-
Bock, F.1
Onderka, J.2
Dietrich, T.3
-
14
-
-
34250315760
-
Topical bevacizumab therapy for corneal neovascularization
-
DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
-
(2007)
Arch Ophthalmol
, vol.125
, pp. 834-836
-
-
DeStafeno, J.J.1
Kim, T.2
-
15
-
-
34548722080
-
Subconjunctival bevacizumab for corneal neovascularization
-
Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1557-1559.
-
(2007)
Graefes Arch Clin Exp Ophthalmol
, vol.245
, pp. 1557-1559
-
-
Erdurmus, M.1
Totan, Y.2
-
16
-
-
47949107165
-
Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis
-
Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
-
(2008)
Cornea
, vol.27
, pp. 743-745
-
-
Carrasco, M.A.1
-
17
-
-
38549140058
-
Subconjunctival bevacizumab injection for corneal neovascularization
-
Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
-
(2008)
Cornea
, vol.27
, pp. 142-147
-
-
Bahar, I.1
Kaiserman, I.2
McAllum, P.3
-
18
-
-
38549107051
-
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization
-
Bock F, König Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008; 246:281-284.
-
(2008)
Graefes Arch Clin Exp Ophthalmol
, vol.246
, pp. 281-284
-
-
Bock, F.1
König, Y.2
Kruse, F.3
-
19
-
-
35348978227
-
Subconjunctival bevacizumab for vascularized rejected corneal grafts
-
Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
-
(2007)
J Cataract Refract Surg
, vol.33
, pp. 1991-1993
-
-
Awadein, A.1
-
20
-
-
40449096035
-
Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome
-
Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
-
(2008)
Cornea
, vol.27
, pp. 70-73
-
-
Uy, H.S.1
Chan, P.S.2
Ang, R.E.3
-
21
-
-
0028953829
-
An SV40-immortalized human corneal epithelial cell line and its characterization
-
Raki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614-621.
-
(1995)
Invest Ophthalmol Vis Sci
, vol.36
, pp. 614-621
-
-
Raki-Sasaki, K.1
Ohashi, Y.2
Sasabe, T.3
-
22
-
-
0024454325
-
Quantification of cells cultured on 96-well plates
-
Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem. 1989;182:16-19.
-
(1989)
Anal Biochem
, vol.182
, pp. 16-19
-
-
Kueng, W.1
Silber, E.2
Eppenberger, U.3
-
23
-
-
33750285956
-
Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells
-
Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
-
(2006)
Br J Ophthalmol
, vol.90
, pp. 1316-1321
-
-
Spitzer, M.S.1
Wallenfels-Thilo, B.2
Sierra, A.3
-
24
-
-
67650578715
-
In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line
-
In press
-
Sharma RK, Chalam, KV. In vitro evaluation of bevacizumab toxicity on a retinal ganglion cell line. Acta Ophthalmol Scand. In press.
-
Acta Ophthalmol Scand
-
-
Sharma, R.K.1
Chalam, K.V.2
|